DK2736533T3 - Selektive indgivelsesmolekyler og anvendelsesfremgangsmåder - Google Patents

Selektive indgivelsesmolekyler og anvendelsesfremgangsmåder Download PDF

Info

Publication number
DK2736533T3
DK2736533T3 DK12820320.5T DK12820320T DK2736533T3 DK 2736533 T3 DK2736533 T3 DK 2736533T3 DK 12820320 T DK12820320 T DK 12820320T DK 2736533 T3 DK2736533 T3 DK 2736533T3
Authority
DK
Denmark
Prior art keywords
molecules
amino acid
seq
peptide
tissue
Prior art date
Application number
DK12820320.5T
Other languages
English (en)
Inventor
Junjie Liu
Jesus Gonzalez
Original Assignee
Avelas Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avelas Biosciences Inc filed Critical Avelas Biosciences Inc
Application granted granted Critical
Publication of DK2736533T3 publication Critical patent/DK2736533T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)

Claims (12)

1. Selektivt indgivelsesmolekyl med formlen I, der har strukturen: [Da-ca] - A- [cm-M] -X-B-[cb-Db] Formel I hvor, X er en peptidlinker, der kan fraspaltes med en matrix-metalloproteinase; A er et peptid med en sekvens bestående af 5 konsekutive glutamater; B er et peptid med en sekvens bestående af 8 konsekutive argininer; ca, cb og cm hver uafhængigt er 0-1 aminosyre; M er en polyethylenglycol- (PEG) polymer med en middelmolekylvægt på 500 Da, 2 kDa, 5 kDa eller 10 kDa; enhver M enten er direkte (cm = 0) eller indirekte (cm =1) bundet til A, B eller X eller til linkere mellem X og A; Da og Db er et par af fluorescerende acceptor- og donordele, der kan undergå Forsters/fluorescensresonansenergioverførsel med hinanden; [Da-Ca] er bundet til N-terminus af A; [cb-Db] er bundet til C-terminus af B; og C-terminus af X er bundet til N-terminus af B.
2. Molekyle ifølge krav 1, hvor ca, cb og cm hver er uafhængigt valgt fra D-cystein, D-glutamat, lysin og para-4-acetyl-L-phenylalanin.
3. Molekyle ifølge krav 1 eller krav 2, hvor X omfatter en aminosyresekvens valgt fra: PLGLAG (SEQ ID NO: 2), PLG-C(me)-AG (SEQ ID NO: 1) og RPLALWRS (SEQ ID NO: 7).
4. Molekyle ifølge et hvilket som helst af kravene 1 til 3, hvor Da og Db er valgt fra Cy5 og Cy7, Cy5 og IRDye750, Cy5 og IRDye800 eller Cy5 og ICG.
5. Molekyle ifølge krav 4, hvor Da og Db er Cy5 og Cy7.
6. Molekyle ifølge et hvilket som helst foregående krav, hvor M er en PEG-polymer med en middelmolekylvægt på 2 kDa.
7. Molekyle ifølge krav 1, hvor molekylet med formlen I har strukturen:
8. Selektivt indgivelsesmolekyle ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i en fremgangsmåde in vivo ved visualisering af et væv af interesse hos et individ.
9. Selektivt indgivelsesmolekyle ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i en fremgangsmåde in vivo ved kirurgisk fjernelse af væv af interesse fra et individ.
10. Selektivt indgivelsesmolekyle til anvendelsen i fremgangsmåden in vivo ifølge krav 9, hvor den kirurgiske margin, der omgiver vævet af interesse, er reduceret.
11. Selektivt indgivelsesmolekyle til anvendelsen i fremgangsmåden in vivo ifølge krav 9 eller krav 10, hvor vævet er cancervæv.
12. Selektivt indgivelsesmolekyle til anvendelsen i fremgangsmåden in vivo ifølge krav 11, hvor cancervævet er: brystcancervæv, colorektalcancervæv, pladeepitelkarcinomvæv, prostatacancervæv, melanomvæv eller thyroideacancervæv.
DK12820320.5T 2011-07-29 2012-07-27 Selektive indgivelsesmolekyler og anvendelsesfremgangsmåder DK2736533T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513287P 2011-07-29 2011-07-29
PCT/US2012/048732 WO2013019681A2 (en) 2011-07-29 2012-07-27 Selective delivery molecules and methods of use

Publications (1)

Publication Number Publication Date
DK2736533T3 true DK2736533T3 (da) 2018-08-06

Family

ID=47629864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12820320.5T DK2736533T3 (da) 2011-07-29 2012-07-27 Selektive indgivelsesmolekyler og anvendelsesfremgangsmåder

Country Status (13)

Country Link
US (6) US9278144B2 (da)
EP (2) EP2736533B1 (da)
JP (1) JP6124150B2 (da)
KR (1) KR102004558B1 (da)
CN (1) CN103874512B (da)
AU (1) AU2012290318B2 (da)
CA (1) CA2841249C (da)
DK (1) DK2736533T3 (da)
EA (1) EA030795B1 (da)
ES (1) ES2683377T3 (da)
HK (1) HK1197184A1 (da)
MX (1) MX350082B (da)
WO (1) WO2013019681A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
ES2890501T3 (es) 2009-03-02 2022-01-20 Massachusetts Inst Technology Métodos y productos para la creación de perfiles enzimáticos in vivo
EP2454271A4 (en) 2009-07-15 2015-08-12 Univ California PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING
EP2736533B1 (en) 2011-07-29 2018-07-04 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
KR102363779B1 (ko) 2013-01-30 2022-02-15 아벨라스 바이오사이언시즈 인코포레이티드 선택적 전달 분자 및 사용 방법
WO2014176284A1 (en) * 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
PL405046A1 (pl) * 2013-08-12 2015-02-16 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Pan Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
US11458208B2 (en) 2016-06-06 2022-10-04 Asclepiumm Taiwan Co., Ltd Desmoglein 2 antibody fusion proteins for drug delivery
WO2018187629A1 (en) * 2017-04-07 2018-10-11 Avelas Biosciences, Inc. Ratiometric fluorescence imaging methods
WO2018237212A1 (en) 2017-06-22 2018-12-27 The Procter & Gamble Company FILMS COMPRISING A WATER-SOLUBLE LAYER AND AN ORGANIC COATING DEPOSITED IN STEAM PHASE
CN110719968A (zh) * 2017-06-22 2020-01-21 宝洁公司 包括水溶性层和气相沉积无机涂层的膜
CN108096255B (zh) * 2017-12-28 2019-11-12 北京大学 地夫可特用于抑制或治疗胰腺癌的用途
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US20220347306A1 (en) * 2018-04-16 2022-11-03 Avelas Biosciences, Inc. Selective delivery of therapeutic and imaging agents
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
CN110075322B (zh) * 2019-05-20 2021-07-06 复旦大学附属妇产科医院 一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用
US20220378780A1 (en) * 2019-09-23 2022-12-01 Neonc Technologies, Inc. Pharmaceutical compositions comprising poh derivatives

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507389A (en) 1982-12-16 1985-03-26 Monsanto Company Determination of collagenase by reacting with peptide substrates
US4466919A (en) 1982-12-16 1984-08-21 Monsanto Company Peptide substrates for mammalian collagenase
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
WO1995013832A1 (en) * 1993-11-16 1995-05-26 Resolution Pharmaceuticals Inc. Immobilized labelling method
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
AU755564B2 (en) 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020009786A1 (en) 2000-04-18 2002-01-24 Tang Y. Tom Novel nucleic acids and polypeptides
US7179784B2 (en) 2001-07-10 2007-02-20 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
DK2489364T3 (da) 2003-11-06 2015-03-02 Seattle Genetics Inc Monomethylvalinforbindelser konjugeret til antistoffer
CA2553040A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP1889047B1 (en) * 2005-06-07 2011-08-10 Centre National De La Recherche Scientifique -Cnrs- Use of conjugates with linkers cleavable by photodissociation or fragmentation for mass spectrometry analysis of tissue sections
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
TW201004647A (en) 2008-05-20 2010-02-01 Sigma Tau Ind Farmaceuti Novel dual targeting antitumoural conjugates
WO2010014236A2 (en) * 2008-07-30 2010-02-04 The University Of North Carolina At Chapel Hill Acylhydrazone-based cleavable linkers
WO2010039496A2 (en) 2008-09-23 2010-04-08 The Regents Of The University Of California Nanocarriers for drug delivery
EP2342223B1 (en) 2008-09-26 2017-04-26 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
KR101095841B1 (ko) 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
WO2010106169A1 (en) 2009-03-19 2010-09-23 General Electric Company Optical imaging agents
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
EP2454271A4 (en) 2009-07-15 2015-08-12 Univ California PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING
US20130142734A1 (en) * 2010-01-12 2013-06-06 Ayelet David Targeted delivery systems for diagnostic applications
JP5580625B2 (ja) 2010-03-03 2014-08-27 住友化学株式会社 メタンスルホン酸アルキルエステル溶液の製造方法
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
ES2708662T3 (es) 2011-02-10 2019-04-10 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Péptidos hidrofóbicos modificados para el diagnóstico hepático específico
EP2736533B1 (en) 2011-07-29 2018-07-04 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
KR102363779B1 (ko) 2013-01-30 2022-02-15 아벨라스 바이오사이언시즈 인코포레이티드 선택적 전달 분자 및 사용 방법
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use

Also Published As

Publication number Publication date
US10570178B2 (en) 2020-02-25
AU2012290318A1 (en) 2014-01-23
JP6124150B2 (ja) 2017-05-10
KR102004558B1 (ko) 2019-07-26
US20160152670A1 (en) 2016-06-02
CA2841249A1 (en) 2013-02-07
CN103874512B (zh) 2016-11-16
HK1197184A1 (en) 2015-01-09
US10239919B2 (en) 2019-03-26
US9371367B1 (en) 2016-06-21
JP2014521661A (ja) 2014-08-28
US20190119327A1 (en) 2019-04-25
WO2013019681A2 (en) 2013-02-07
EA030795B1 (ru) 2018-09-28
EP2736533A2 (en) 2014-06-04
EP3473273A1 (en) 2019-04-24
ES2683377T3 (es) 2018-09-26
MX350082B (es) 2017-08-24
US9840537B2 (en) 2017-12-12
KR20140063587A (ko) 2014-05-27
EA201490385A1 (ru) 2014-07-30
US20150031852A1 (en) 2015-01-29
US20170044214A1 (en) 2017-02-16
CA2841249C (en) 2023-09-26
MX2014001138A (es) 2014-07-22
EP2736533A4 (en) 2015-03-04
AU2012290318B2 (en) 2016-09-01
US9504763B2 (en) 2016-11-29
US20160220707A1 (en) 2016-08-04
CN103874512A (zh) 2014-06-18
EP2736533B1 (en) 2018-07-04
US9278144B2 (en) 2016-03-08
US20180057536A1 (en) 2018-03-01
WO2013019681A3 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
US10570178B2 (en) Selective delivery molecules and methods of use
US20200376013A1 (en) Selective drug delivery compositions and methods of use
US10363313B2 (en) PSMA ligands and uses thereof
WO2019183633A1 (en) Psma targeted conjugate compounds and uses thereof
US20220347306A1 (en) Selective delivery of therapeutic and imaging agents
US20210079039A1 (en) Compositions and methods for the selective delivery of therapeutic and imaging agents
KR20240066128A (ko) 암의 검출 및 치료를 위한 방법 및 제제